The feasibility of combining the Lym-1 monoclonal antibody (MoAb) with interferon-y (IFN-y) in the treatment of chronic lymphocytic leukemia (CLL) was evaluated. We used an in vitro tumor lysis model that incorporated fresh CLL cells from 21 different patients as targets for two distinct normal human leukocyte effector subsets, neutrophils, and peripheral blood mononuclear cells (PBMCs). Lym-1 antigen (Lym-lAg) expression varied greatly and did not correlate with the expression of other CLL-associated antigens such as CD5, CD19, or HLA-DR. CLL cells were not lysed by neutrophils alone or with IFN-y in the absence of Lym-1. Neutrophil Lym-1-dependent cytotoxicity (ADCC) in the absence of IFN-7 was weak and inconsistent. 1FN-y exposure induced MoAb-dependent lysis of 80% of 21 CLL targets and resulted in an eightfold augmentation of neutrophil ADCC against the remainder. Cytotoxicity correlated directly and positively with Lym-1-Ag expression. Confirmation of the need for
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HERAPY WITH monoclonal antibodies (MoAbs) has
T resulted in limited responses in virtually all reported trials. ' In an effort to improve these response rates, investigators have attempted to enhance the potency of the antibody itself (by linking it to lethal substances such as radioisotopes, drugs, or toxins) or to improve the host's ability to eliminate antibody-coated tumor targets by augmenting cellular immunity with recombinant cytokines. Three preliminary clinical trials have failed to demonstrate a significant advantage to cotreatment with interferon-a (IFN-a) and anti-idiotype MoAbs in B-cell lymphomas,' IFN-y, and the C017 1A MoAb in patients with colon cancer: and IFN-a and an anti-G,, MoAb in melanoma: These trials were based on preclinical data that suggested the efficacy of cytokine plus MoAb cotherapy either in vivo in a mouse model or in vitro using human effector cells and tumor cell lines.
In an effort to choose the optimal cytokine for a clinical trial, we have examined several for their ability to enhance cell-mediated killing of human tumor cell lines. Previously, we characterized the influence of interleukin-2 (IL-2) on peripheral blood mononuclear cell (PBMC)-mediated killWe discovered that PBMCs exposed to IL-2 either in vivo or in vitro displayed markedly enhanced MoAbindependent and MoAb-dependent (ADCC) lysis of tumor cell lines, including those derived from chronic lymphocytic leukemias (CLL).
In separate studies, neutrophils were consistently potent mediators of ADCC but only in the presence of IFN-T.~,' PBMCs treated with IFN-y produced significantly greater ADCC than untreated PBMC, but the degree of augmentation was far less than that observed with similarly treated neutrophils. Enhancement of ADCC by these cytokines (IL-2 and PBMCs; IFN-y and neutrophils) shared many common properties that would be desirable in a clinical trial: brief cytokine exposure primed the effector cells, clinically attainable concentrations were effective, and ADCC was augmented at low antibody concentrations and low effector-to-target ratios.
In this study, we compared PBMC and neutrophil killing After informed consent, 21 patients with CLL, 11 females and 10 males, were entered into this study. The diagnosis of CLL was established by standard clinical and laboratory criteria by one of us (T.H. or L.V.) and by immunophenotypic analyses using a panel of B-and T-cell markers (Table 1 and Fig 1) . The percent of Lym-1-positive cells was determined for each patient proximate to the assay.
Fresh CLL cells were obtained from whole blood by venipuncture and collected into sterile Vacutainer tubes (Becton Dickinson) containing preservative-free heparin. Blood was diluted with RPMI 1640 medium 1:l and layered onto Ficoll-Hypaque, specific gravity 1.007 (Pharmacia, Piscataway, NJ). CLL cells were ob-
CLLpatients.
tained from the but@ coat as described." Viability was always greater than 98%.
Efector cells. Effector cells were obtained from the whole blood of normal donors after informed consent, as described?,' Briefly, whole blood was layered onto neutrophil isolation medium (Los Alamos Diagnostics, Los Alamos, NM) and effector cell subsets isolated by centrifugation at 4OOg for 30 minutes at room temperature (RT). The upper buRy coat consisted of PBMCs and the lower of neutrophils. The purity of these preparations was as follows (mean percent f 1 SD): PBMCs were 86.4% f 3.0% lymphocytes, 9.3% f 1.9% monocytes, and 4.3% f 1.9% neutrophils. Neutrophils were 98.0% f 0.9% neutrophils, 0.2% f 0.2% monocytes, and 2.0% f 1.1% lymphocytes (n = 10). These results were obtained from an ES/T 8000 Analyzer (Ortho Diagnostics, Raritan, NJ) and confirmed by microscopic inspection of Wright's stained cytospin preparations and immunofluorescence on a flow cytometer (FACScan; Becton Dickinson, Sunnyvale, CA) as described. ' IFN-y was purchased from Collaborative Research Inc (Bedford, MA). Activity was determined by inhibition of encephalomyocarditis (EMC) virus propagation in WISH amnion cells. The IFN-y was greater than 98% pure by SDS-PAGE, had 2.9 x lo7 U/mg protein, 0.069 endotoxin unitsi5 x lo5 U, and its amino acid composition correlated greater than 99% with native human IFN-y. Recombinant human IL-2 was provided by Hoffman-La Roche (Nutley, NJ), had a specific activity of 1.5 x 10' Uimg protein, undetectable endotoxin levels, and was greater than 95% pure.
Surface marker phenotyping of cells was performed by indirect immunofluorescence on a flow cytometer as described?." A minimum of 2,500 cells were counted per test. Immunofluorescence is expressed as percent positive cells and by
Recombinant human cytokines.
Flow cytometric analysis. For personal use only. on October 30, 2017. by guest www.bloodjournal.org From FgimL and 100 U/mL, respectively. After 16 to 18 hours of incubation at 37T, tumor cell lysis was measured by determining the amount of "Cr released by absorption of cultured supernatant into harvesting frame filters (Skatron Corporation, Sterling, VA) followed by counting in a gamma counter (Beckman Model 5500b). The percent specific lysis was determined by the following equa-
where E is the average of triplicate sample counts per minute for experimental, S is the spontaneous release, and M is the maximal release for wells containing only target cells that were treated with 1% Triton X-100 detergent. In general, the SD of triplicates was less than 15%. In 16-to 18-hour assays, mean CLL cell spontaneous 'lCr release was less than 40% of maximum release (mean of 39.7% f 12.5% SD; n = 69). Tests in which this release exceeded 60% were excluded from analysis. For 4-hour assays, CLL cell spontaneous release averaged 24.4% (*10.1% SD; n = 5). For Raji cells, spontaneous release was always 525%. The higher spontaneous release from fresh tumor cells is in accord with reports using fresh lymphoma cells and ovarian cancer Lytic units (LU) were derived from the cytotoxicity curves generated by a range of E:T ratios as and were calculated by a modification of the linear regression line of best fit, as reported by Pross et al. '5 One LU is defined as the number of cells required to lyse 33% of the targets and is expressed per lo7 effector cells, so that the value increases with increasing Cytotoxicity assay. lytic activity. A minimum of four E:T ratios were used to calculate LU; however, in most experiments five or more E:T ratios were used. The viability of neutrophils at the end of the ADCC assay was between 95% and loo%, and they were metabolically active (as determined by reduction of the tetrazolium salt MTT, as described).6 In addition, the cytoplasmic contents of neutrophils disrupted by sonication did not cause "Cr release; thus, CLL cell killing was specific and not due to release of intracellular contents from dead or dying effector cells. This finding is similar to what we reported for the effect of neutrophil contents (obtained by freezethaw) on Raji targets. 6 Statistical analyses. Statistical analyses were accomplished by use of the paired t-test and the Pearson correlation coefficient.
RESULTS
Immunophenotyping of freshly isolated CLL cells was performed on the same day as cytotoxicity assays (Table 1) . Epstein et a1 had previously reported that Lym-1 stained 40% of CLLs (n = lo).* We needed to determine the level of Lym-1-Ag expression (as estimated by MF) and the percent of total CLL cells that were positive. Immunophenotyping would also determine whether the majority of the targets were tumor cells. The Lym-1-Ag was detected in a proportion of every CLL sample that we surveyed, but the percent of positive cells varied widely (mean 41%; range, 13% to 76%). The intensity of expression was less variable with a MF average of 522 and a range of 425 to 640.
Lym-1-Ag expression was similar to other CLL-associated markers such as CD5 (MF average 421), CD19 (MF average 461), and HLA-DR (MF average 652), but was not detected on as many CLL cells (CD5, CD19, and HLA-DR were positive on 81%, 82%, and 84% of the total, respectively). Of interest, Lym-1 binds to a variant HLA-DR molecule and it appears to be discoordinately regulated compared with nonpolymorphic DR antigens. Most of the cells that were used as targets in these experiments were Fig l. Contamination with the major lymphocyte subset in normal PB, T cells, was minor (mean of 11% of the total were CD3+) and monocyte content (as estimated by CD14 expression) was negligible (Fig 1) .
Neutrophil-mediated killing of CLL cells was examined (Fig 2 and Table 2 ). Neutrophils alone or with IFN-y were unable to lyse CLL cells. Neutrophils plus Lym-1 in the absence of IFN-y lysed CLL targets only when Lym-1-Ag expression was high (patients RG and ZG). The addition of IFN-y consistently induced or upregulated (fourfold to 17-fold increase) Lym-1-dependent neutrophil-mediated tumor lysis. The varying levels of cytotoxicity that were observed suggested that there was a correlation with CLL Lym-1-Ag expression. Indeed, when LU or percent cytotoxicity at a 1OO:l E:T ratio were compared with Lym-1-Ag expression there was a strong positive correlation (Fig 3A, P < .001,r = .677forcytotoxicity; Fig3B,P < .001,r = .653
for LU). The data in Fig 3A and B are a compilation of the results presented in Table 2 and, thus, effector cell variability has not been completely eliminated. However, effectors from one donor (LV) were used against five different targets and there was a strong correlation between lysis and Lym-1 antigen expression. Examined in another way, there was a 329% increase in lysis when CLL targets with greater than 50% Lym-1-Ag expression were compared with those with less than 50%. Also, CLL targets with less than 50%
Lym-1-Ag expression all had LU values of zero when incubated with neutrophils and Lym-l in the absence of
The tumoricidal capability of PBMCs was examined simultaneously (Fig 4) . PBMCs alone, with IL-2, or with IFN-7.
'0° r tResults are expressed as LU 33%/107 effector cells. In all experiments, neutrophils (NEUTs) alone, IFN-y alone, or Lym-1 plus IFN-y in the absence of neutrophils were ineffective. A dash means not done. $Only percent cytotoxicity at a 1OO:l E:T ratio is shown because low effector cell yield did not allow a complete LU 33%/10' cells to be performed.
IFN-y were unable to lyse CLL cells in an antibodyindependent fashion. PBMC ADCC was negligible with Lym-1 alone or in combination with IFN-y (P not significant compared with PBMCs alone). Cytotoxicity by PBMCs plus IL-2 and Lym-1 was slightly better, but the majority of this apparent increase was due to assays that used ZG CLL cells that expressed the greatest amount of Lym-1-Ag. For most CLL targets, the combination of PBMCs plus IL-2 and Lym-1 was ineffective. Indeed, if this one patient's cells are excluded from the analysis, cytotoxicity was negligible for the PBMC plus Lym-1 and IL-2 combination (LU values were [mean ? 1 SD] 0.7 ? 2.3 and percent cytotoxicity at 1OO:l E:T ratio values were 13 -C 11). The same PBMCs were simultaneously tested for their ability to lyse Raji targets. PBMCs were always able to mediate ADCC against Raji cells with Lym-1 (not shown) or in conjunction with Lym-1 plus IL-2 (Fig 4) , thus, their lytic functions were intact.
Cytotoxicity was examined after 4 and 16 hours to determine whether duration of contact between effectors and CLL targets influenced lysis ( Table 3) . As in our prior studies: a longer duration of contact between effectors and targets resulted in a higher level of lysis against high or low expressors of the Lym-1-Ag. As before, neutrophils were much more effective mediators of CLL lysis than PBMCs.
To confirm that IFN-y-enhanced, neutrophil-mediated lysis of CLL targets was due to interactions between Table 2 , while all 21 values in B are from Table 2 . The abscissae show percent Lym-I-Ag-positive cells out of total CLL cell pool as determined by fluorescence on a flow cytometer (2,500 cells counted per experiment and compared with a negative antibody control).
FcyR-bearing neutrophils and the Fc portion of Lym-1, SpA was added to the ADCC assay to determine whether it could inhibit the reaction (Table 4) . We have previously shown that SpA binds to the Fc portion of Lym-1 and inhibits antibody-dependent, but not antibody-independent, lysis of Raji cell^.^^^ SpA profoundly inhibited Lym-ldependent CLL cell lysis (mean of 80% with a range of 54% to 100% inhibition). In addition, UPC-10, a nonreactive isotype-matched MoAb, was unable to mediate lysis (not shown).
In our previous studies, IFN-y acted exclusively on the neutrophil by upregulating the type I Fc receptor, CD64, to enhance ADCC and had no detectable effect on the IFN-y has been reported to upregulate expression of HLA-DR molecules, and because Lym-1 reacts with a variant DR molecule, it was possible that augmentation of ADCC was due to upregulation of the Lym-1-Ag as well as by enhancement of neutrophil functions. CLL cells from seven patients were incubated with or without IFN-y for 24 hours and the level of Lym-1-Ag expression was estimated by indirect immunofluorescence on a flow cytometer (Table  5) . If the level of Lym-1-Ag was high before incubation, it tended to decrease with IFN-y exposure, and if it was initially low, it increased. However, the percent positive cells and the MF from both groups were not markedly different at the end of the incubation period; thus, alterations in Lym-1-Ag expression were unlikely to account for the enhancing effects of IFN-y. Additionally, pretreatment of CLL targets from four patients with 200 U/mL of IFN-y for 3 hours did not enhance their susceptibility to lysis by neutrophils plus Lym-1 (n = 4, not shown).
DISCUSSION
The major findings of this study are the following: (1) For produce responses in clinical trials may be due to any of the following: high levels of circulating free antigen, formation of human antimouse antibodies (HAMA), antigenic modulation, poor tissue penetration, insufficient level of tumor cell target antigen expression, or emergence of antigennegative mutants. However, a relative or absolute failure of host effector mechanisms to destroy tumor cells may be the major factor if the MoAb localizes to tumor ~ites.'.'~-'' Nonhuman animal models support this contention and emphasize the importance of using an antitumor MoAb capable of activating immune effector circuits, most importantly ADCC."~21 The Lym-1 MoAb was felt to be an excellent therapeutic candidate because many of the barriers to effective serotherapy mentioned above did not apply. We had previously demonstrated that PBMCs exposed to IL-2 in vitro or PBMCs harvested from cancer patients receiving IL-2 in vivo displayed a marked enhancement of ADCC and antibody-independent lysis of a panel of Lym-1-Ag expressing human tumor cell lines, including three For personal use only. on October 30, 2017. by guest www.bloodjournal.org From different CLL cell lines.' IFN-y had a similar effect on PBMC ADCC.627 However, under identical treatment conditions PBMCs were unable to lyse fresh CLL cells (Fig 4) . A similar dichotomy between the susceptibility of cultured cell lines and fresh tumors to lysis has been observed with IL-;?-activated natural killer (NK) cells and leukemic targ e t~.~' The reasons for this are unknown and the possibilities include the following: (1) Although IFN-y enhanced neutrophil ADCC against CLL cells, IFN-y and IL-2 may have decreased PBMC lytic functions. This possibility is unlikely because we and others have reported that IL-2 and IFN-y have consistently and significantly augmented PBMC ADCC against a variety of human tumor targets, including, as mentioned above, CLL cell lines.5,6,36.37,394* (2) IFN-y and IL-2 have been reported to exert a protective effect on fresh tumor cells and tumor cell lines and render them resistant to NK or lymphokine-activated killer (LAIC) cell-mediated antibody-independent Lahat et a1 reported that IL-2 and IFN-y enhanced NK activity against fresh hairy cell leukemia targets, but that exposure of targets to these cytokines before the assay decreased their susceptibility to l~sis.4~ IFN-y was reported to have a similar effect on melanoma cell lines in PBMC ADCC, especially at IFN-y concentrations greater than 100 U/mL.37 Unless this protective effect is somehow unique to a PBMC/CLL combination, it cannot explain our results because IFN-y did not have this effect on any bther effector/target combination5s6 ( Table 3) . (3) CLL cells are susceptible to neutrophil lytic mechanisms but resistant to those mediated by PBMCs. While this hypothesis is possible, because neutrophil and PBMC lytic mechanisms are different, we feel that a more likely explanation is that (4) PBMC lytic functions were not triggered by the Lym-l/Lym-1-Ag array on the surface of most CLL cells. We feel that this possibility is likely because PBMCs were capable of ADCC against CLL cells, albeit minimal, and there was evidence of enhancement by IL-2 (Fig 4) . However, conditions had to be optimal (presence of IL-2, highest Lym-1-Ag-expressing CLL targets, 1OO:l E:T ratio) for PBMC ADCC.
The reasons why neutrophil lytic mechanisms were more efficient at killing CLL targets are not dear. We have demonstrated that the effector cell within the PBMC leukocyte subfraction exclusively used the type I11 IgG Fc receptor (FcyR), CD16, to mediate lysis of Raji targets in conjunction with L~m -1 .~ The Lym-l/Lym-1-Ag surface complex on fresh CLL cells may not sufficiently perturb PBMC CD16 such that a stimulus threshold is exceeded with subsequent triggering of the lytic mechanism. In contrast, we have demonstrated a specific upregulation of CD64 (FcyR I) by IFN-y that appears to be critical for neutrophil ADCC with L~m -1 .~~' Thus, triggering of the neutrophil's lytic mechanism via CD64 may be more efficient at killing fresh CLL cells. Although this study did not address which leukocyte FcyRs were functionally important in lysis of CLL cells, it is reasonable to conclude that they were the same. Further examination of antibodydependent leukocyte killing of CLL cells will be necessary to identify functionally important FcyRs.
Neutrophils may be an ideal effector cell to exploit in vivo against CLL in combination with a MoAb for a variety of reasons: (1) neutrophils have not been reported to be impaired in CLL patients, as opposed to descriptions of numerical and functional deficiencies of T and NK cells16347; (2) they are potent mediators of antibody-dependent lysis of fresh CLL cells in conjunction with IFN-y ( Table 2) ; (3) neutrophils are the most abundant leukocyte subset in humans and can be qualitatively and quantitatively augmented by growth factors such as G-CSF and GM-CSF@'; (4) neutrophils have been shown to be capable of infiltration into tumor sites in experimental nonhuman animals and in human^^^.^'; and (5) CLLpatients are much less likely to form HAMA than other cancer patients, and this may allow multiple treatment courses. 51 IFN-y has advantages and disadvantages as a cytokine to combine with an MoAb for CLL therapy. IFN-y monotherapy has resulted in responses in CLL.52 Levels of IFN-y used in our study can be attained in vivo. Schiller et al reported that IFN-y levels of approximately 170 to 670 U/mL were detected 120 hours after initiation of a 5-day continuous intravenous infusion at 700 ~g/d/patient.'~ It is difficult to assess whether this level would be reached with IFN-y monotherapy because IFN-y was coadministered with IFN-P in this study. Importantly, IFN-y side effects are treatable, generally tolerable, and reversible with few reports of grade I11 t o~i c i t y .~* ,~~ Dose-dependent neutropenia is the main disadvantage of IFN-y if neutrophil ADCC augmentation is the goa1.3~34~'2~53 However, neutropenia may not preclude combination with a MoAb because the optimal antiproliferative dose of IFN-y may be higher than the concentration required to enhance neutrophil ADCC, ie, the optimal immunomodulatory dose. Results consistent with this contention have been reported for monocyte ADCC.'S~~ In summary, we have shown the complexities involved in designing clinical protocols based on preclinical data involving MoAbs and recombinant cytokines. It seems clear that if an in vitro model is to have utility in the design of clinical trials, or have predictive value in the follow-up of alterations in immune parameters after cotreatment of patients with MoAbs and cytokines, the model should incorporate components that are as relevant as possible. This will allow for the optimal design of treatment strategies that exploit particular immune effector mechanisms such as neutrophil ADCC. The results of this study suggest that IFN-y would be a reasonable cytokine to combine with Lym-1 in a phase I immunotherapy trial of selected CLL patients.
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